Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 14/20 | 0.55 |
| ▸ | PTGDR | Q13258 | 10/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 4/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30573130 | 0.88 | FABP4 (0.66) | TBXA2RPTGDRFABP4PDE2A | |
| SCHEMBL24155321 | 0.88 | FABP4 (0.66) | TBXA2RPTGDRFABP4PDE2A | |
| SCHEMBL25935932 | 0.85 | FABP4 (0.54) | TBXA2RPTGDRFABP4F10PDE2A | |
| SCHEMBL30317268 | 0.82 | FABP4 (0.63) | TBXA2RPTGDRFABP4 | |
| SCHEMBL28983470 | 0.81 | FABP4 (0.57) | TBXA2RPTGDRFABP4PDE2A | |
| SCHEMBL30317536 | 0.81 | FABP4 (0.57) | TBXA2RPTGDRFABP4PDE2A | |
| SCHEMBL28983479 | 0.79 | FABP4 (0.62) | TBXA2RPTGDRFABP4 | |
| SCHEMBL26246952 | 0.78 | FABP4 (0.51) | FABP4F10HDAC6 | |
| SCHEMBL30317431 | 0.77 | FABP4 (0.64) | TBXA2RPTGDRFABP4 | |
| SCHEMBL28983430 | 0.75 | FABP4 (0.67) | FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331673-A1 | COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE | CRESCENTA BIOSCIENCES (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331673-A1 | COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE | FABP4, FABP1, FABP3 | TBXA2R 590/4885PTGDR 770/4885FABP4 1/4885 |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | TBXA2R 1424/4885PTGDR 2965/4885FABP4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.